Severe Kidney Disease Risk and Your Genetics

What is severe kidney disease risk?

Severe kidney disease risk reflects the likelihood that a person's kidneys may progressively lose function to the point of requiring dialysis or a transplant — a condition known as end-stage renal disease (ESRD). The kidneys filter waste, balance fluids, and regulate blood pressure. When sustained damage erodes filtering capacity over years, that loss becomes life-altering. Genetic factors influence who is most susceptible, and for severe kidney disease, the genetic signal is among the sharpest in all of human genomics.

~37 million adults in the United States live with chronic kidney disease. Approximately 40% of all new end-stage renal disease cases are attributed to diabetic nephropathy — kidney damage driven by long-term high blood sugar.

Kidney disease rarely announces itself early. By the time symptoms appear — swelling, fatigue, reduced urine output — meaningful function may already be gone. That is why genetic context matters: it can surface elevated susceptibility years before clinical signs emerge, creating a window for monitoring and protective action.

Research base: Robust.

The genetics behind severe kidney disease risk

Two genes anchor this trait's genetic architecture: APOL1 and TCF7L2. Each operates through a distinct biological pathway, and together they trace two of the most well-established routes from genetic variation to kidney failure.

APOL1: An evolutionary trade-off written in kidney cells

APOL1 encodes apolipoprotein L1, a protein that circulates in the bloodstream as part of high-density lipoprotein (HDL) particles. Its most striking property is the ability to kill certain trypanosomes — the parasites responsible for African sleeping sickness. When APOL1 protein encounters a susceptible trypanosome, it inserts into the parasite's membrane and forms ion channels that destroy it from within.

In sub-Saharan Africa, where Trypanosoma brucei rhodesiense is endemic, older forms of APOL1 became less effective as the parasite evolved countermeasures. Two newer variants — referred to as APOL1 risk variants G1 and G2 — arose specifically as counter-adaptations, restoring the trypanolytic ability that older variants lost. This was an evolutionary advantage of profound magnitude: surviving a disease that killed before reproductive age. The variants spread through populations of West African ancestry and remain common today.

The cost of that advantage became apparent only in modern medicine. In the kidney, APOL1 is expressed in podocytes — specialized cells that wrap octopus-like extensions around the tiny capillaries of the glomerulus, forming the filtration barrier that keeps proteins in the blood while allowing waste through. When a person inherits two copies of APOL1 risk variants G1 and G2 (one from each parent), those variants alter the protein's behavior inside podocytes under physiological stress. The risk variant protein forms aberrant ion channels that damage podocyte membranes, triggering a cascade of scarring that can destroy the filtration units of the kidney.

The kidney conditions most strongly linked to this genotype include focal segmental glomerulosclerosis (FSGS) — a pattern of scarring in the glomeruli — as well as hypertension-attributed kidney disease and HIV-associated nephropathy (HIVAN). In each case, the APOL1 high-risk genotype dramatically amplifies susceptibility, particularly when environmental triggers such as high blood pressure or HIV infection are also present.

Approximately 13% of African Americans carry two APOL1 risk variants — the high-risk genotype associated with elevated kidney disease susceptibility. The variants are nearly absent in populations of European, East Asian, or South Asian ancestry, making this one of the most ancestry-concentrated genetic risk signals in medicine.

This ancestry concentration deserves careful framing. APOL1 risk variants evolved because they protected against a lethal parasitic disease. Their effect on kidneys is a biological trade-off — not a flaw, not a deficit, and not destiny. The majority of people who carry the high-risk genotype do not develop end-stage renal disease. Environmental stressors, blood pressure control, diabetes status, HIV exposure, and access to monitoring all shape whether the genetic susceptibility translates into clinical kidney damage.

TCF7L2: The diabetes-to-kidney pathway

TCF7L2 encodes transcription factor 7 like 2, a protein that regulates gene expression through the Wnt signaling pathway. In pancreatic beta cells, TCF7L2 controls insulin gene transcription and beta cell survival. Certain TCF7L2 variants impair this regulatory function, progressively reducing insulin secretion and increasing susceptibility to type 2 diabetes — making TCF7L2 one of the most replicated type 2 diabetes genetic signals identified across large genome-wide studies.

The connection to kidney disease flows through a well-established causal chain. Type 2 diabetes is the single largest driver of end-stage renal disease worldwide. Chronic hyperglycemia — persistently elevated blood glucose — damages the delicate capillaries of the glomerulus, thickens the filtration membrane, and triggers inflammatory changes that progressively scar kidney tissue. This process, diabetic nephropathy, accounts for roughly 40% of all new dialysis cases. TCF7L2 variants that elevate type 2 diabetes risk therefore carry a downstream kidney consequence: a pathway running from pancreatic beta cell dysfunction through chronic high blood sugar to kidney filtration failure.

These two genes — APOL1 acting directly in kidney podocytes, TCF7L2 acting through the diabetes-nephropathy route — represent distinct biological mechanisms that both converge on the same outcome: severe, progressive kidney damage.

What the research says

A landmark 2024 study published in Science by Verma and colleagues analyzed the genetic architecture of 2,068 traits simultaneously in the VA Million Veteran Program (MVP), one of the largest and most ancestrally diverse genomic cohorts ever assembled. The MVP's deliberately inclusive recruitment of African American veterans gave the study particular power to detect ancestry-concentrated signals — including those driven by APOL1 risk variants. The severe kidney disease associations with APOL1 and TCF7L2 emerged from this comprehensive, diversity-centered analysis, adding to an already substantial body of evidence built across multiple independent cohorts over more than a decade.

The APOL1 story is one of the most replicated findings in nephrology genetics. The robust confidence tier assigned to this trait reflects that independent replication: the APOL1 high-risk genotype has been associated with FSGS, hypertension-attributed ESRD, and HIVAN across diverse study populations and analytical approaches. The TCF7L2-diabetes-kidney pathway is similarly well-established, anchored in the epidemiological fact that diabetic nephropathy is the leading cause of dialysis initiation worldwide.

What the research does not tell us is precisely who among those carrying these variants will develop severe kidney disease. Penetrance is incomplete. The genetic signal defines susceptibility, not certainty. Studies consistently find that blood pressure control, glycemic management, avoidance of kidney-toxic exposures, and early clinical monitoring substantially alter outcomes — emphasizing that the genetic signal is a call to informed monitoring, not a fixed prognosis.

How severe kidney disease risk affects you

A higher score on this trait reflects a stronger genetic signal toward severe kidney disease susceptibility. Because higher is detrimental for this trait, the framing matters: a higher result does not mean kidney disease is inevitable, but it does mean the biological factors that raise risk are more prominently present in your genome.

For those of West African ancestry, APOL1 is likely the dominant contributor. For others, TCF7L2's diabetes-mediated pathway may play a larger role. In practice, both pathways can coexist, and kidney health sits at the intersection of genetics, blood pressure, blood sugar, lifestyle, and access to monitoring.

The populations most affected by severe kidney disease include Black Americans, in whom both APOL1 variant prevalence and structural health disparities — including reduced access to early nephrology care, higher rates of untreated hypertension, and systemic barriers to diabetes management — converge to produce disproportionate rates of ESRD. Understanding the genetic component of this disparity is one step toward addressing it with targeted, equitable clinical attention.

Kidney disease is also a cardiovascular amplifier: reduced kidney function accelerates arterial stiffening, raises blood pressure, and increases heart disease risk. The connections between this trait, hypertension, and cardiovascular health are not coincidental — they are mechanistically linked.

Working with your severe kidney disease risk result

Genetic susceptibility to severe kidney disease is not a fixed outcome. Several well-established strategies can substantially reduce the likelihood that a genetic signal translates into kidney damage.

Blood pressure control is the single most important modifiable factor. Hypertension accelerates kidney damage across all risk genotypes and is particularly destructive in the context of APOL1 risk. Medications in the ACE inhibitor and ARB classes not only lower blood pressure but also reduce pressure within the glomerular capillaries, directly protecting kidney filtration units. Reaching and maintaining a blood pressure target below 130/80 mmHg is widely recommended for those at elevated kidney risk.

Preventing and managing type 2 diabetes protects kidneys through the TCF7L2 pathway. Weight management, a diet low in refined carbohydrates and ultra-processed foods, and regular physical activity each reduce the risk of progressing from genetic susceptibility to clinical diabetes. For those who already have type 2 diabetes, glycemic control — keeping HbA1c near target — substantially slows the rate of kidney function decline. Newer medication classes including SGLT2 inhibitors have demonstrated direct kidney-protective effects beyond glucose control.

Avoid kidney-toxic exposures where possible. Non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen and naproxen) reduce blood flow to the kidneys and should be used sparingly or avoided by those at elevated kidney risk. Contrast dye used in certain imaging studies carries nephrotoxic risk; flagging kidney risk history to radiologists allows for protective protocols. Certain antibiotics are nephrotoxic at high doses — inform all prescribers of your kidney risk context.

Annual kidney function monitoring is strongly advisable for high-risk individuals. Two simple tests — estimated glomerular filtration rate (eGFR, from a standard blood draw) and the urine albumin-to-creatinine ratio (uACR, from a urine sample) — can detect kidney function decline and early filtration barrier damage years before symptoms appear. Early detection allows early intervention.

For those carrying two APOL1 risk variants: HIV prevention and prompt treatment matter for kidney health. HIV-associated nephropathy (HIVAN) is dramatically more common and more severe in people with the APOL1 high-risk genotype. HIV prevention strategies and, for those living with HIV, early initiation of antiretroviral therapy, are kidney-protective alongside their other benefits.

Discuss this result with a clinician who understands APOL1 biology. Nephrologists and some primary care clinicians are increasingly familiar with APOL1 risk. A conversation about your result, ancestry, and current blood pressure and metabolic status can translate genetic information into a concrete, personalized monitoring plan.

Related traits and genes

Severe kidney disease does not occur in biological isolation. Several related traits tracked by ExomeDNA sit in the same physiological network.

Chronic kidney disease risk reflects the earlier-stage continuum of kidney function decline — the territory that, if unmanaged, progresses toward the severe end captured by this trait. Understanding your chronic kidney disease risk score alongside this one provides a fuller picture of where on the severity spectrum your genetic signal sits.

Type 2 diabetes risk captures the TCF7L2-anchored pathway directly. Because diabetic nephropathy is the leading cause of ESRD, elevated type 2 diabetes genetic risk is also upstream kidney risk. These two traits should be interpreted together.

Hypertension risk matters because blood pressure is both a cause and a consequence of kidney function decline. The hypertension-kidney feedback loop makes managing blood pressure among the highest-leverage actions available to those with elevated kidney disease susceptibility.

The cardiovascular health score and inflammatory response traits connect to kidney disease through shared vascular and inflammatory mechanisms — arterial stiffening, endothelial dysfunction, and chronic low-grade inflammation each accelerate both cardiovascular and kidney damage.

For a deeper look at the biology of the gene most central to this trait, visit the APOL1 gene page.

Frequently asked questions